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Prasugrel versus clopidogrel in stent-assisted
coil embolization of unruptured intracranial
aneurysms
Jacques Sedat1, Yves Chau1, Jean Gaudart2, Marina Sachet1,
Stephanie Beuil3 and Michel Lonjon4
Abstract
Background: Thromboembolic complications are the main problem in stent-assisted coil embolization of unruptured intra-
cranial aneurysms. The combination of aspirin and clopidogrel is generally used to decrease these complications, but some
patients do not respond to clopidogrel and have a higher risk of stent thrombosis. In cardiology, clinical trials have shown
that prasugrel reduced the incidence of ischaemic events in patients with acute coronary syndrome compared with
clopidogrel but, according to several authors, prasugrel would produce an increased risk of cerebral haemorrhagic
complications.
Objective: The purpose of this study was to determine whether prasugrel would be more effective than clopidogrel in
reducing procedural events in patients with an unruptured aneurysm treated endovascularly with coils and stent.
Materials and methods: Two hundred consecutive patients with intracranial aneurysms were treated using coiling and
stenting procedures. The first 100 patients were administered a dual antiplatelet of aspirin and clopidogrel, while the
remaining 100 patients were administered a dual antiplatelet of aspirin and prasugrel. In each group data were collected on
procedural and periprocedural haemorrhagic and ischaemic complications.
Results: Aneurysmal occlusion and haemorrhagic complications rates were identical in both groups. The number of
thromboembolic events observed in the two groups of our study did not differ significantly, but the prasugrel group included
more wide-neck aneurysms and more flow-diverted stents. Moreover, complications in the prasugrel group were more
benign, explaining the significant difference in clinical outcomes between the two groups on Day 30.
Conclusions: Prasugrel reduces the clinical consequences of thromboembolic complications of endovascular treatment with
stenting and coiling of unruptured intracranial aneurysms.
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Introduction
Background/objectives
When paired with coiling, stenting procedures are able
to decrease the risk of aneurysm recurrence after the
endovascular treatment of intracranial aneurysms.
However, this type of intervention yields higher risk
rates of thromboembolic complications when com-
pared to regular coiling procedures.1–12
The combination of aspirin and clopidogrel – which
is generally used in these procedures – produces
variable results among patients, especially given the
fact that there are patients that do not respond to clo-
pidogrel. For these groups of patients, the risk of stent
thrombosis or brain ischaemia is signiﬁcantly
higher.13,14
Some authors reported a number of cases in which
endovascular cerebral procedures carried out after the
administration of a combination of aspirin and
prasugrel yielded good clinical results, but produced
an increased risk of cerebral haemorrhagic
complications.15,16
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This prospective study was carried out with the
express agreement of the hospital’s ethics committee
and aimed to evaluate the eﬀectiveness and risks asso-
ciated with coiling and stenting treatments in cases of
non-ruptured intracranial aneurysms following the
administration of aggregation inhibiting drugs – i.e.
aspirin and prasugrel – in preoperative, intraoperative
and postoperative conditions. The data collected for
this study includes procedural and periprocedural
haemorrhagic and ischaemic complications, as well as
angiographic and clinical results collected both imme-
diately after the intervention and six months following
the intervention. The results were compared to those
produced by a reference group which received treat-
ment with clopidogrel and aspirin.
Patients and methods
Study design
The study draws a comparison between two consecu-
tive groups of patients which were subjected to coiling
and stenting procedures in order to treat non-ruptured
aneurysms (or aneurysm recurrence). One of these
patient groups was administered a dual antiplatelet of
aspirin and clopidogrel, while the other was adminis-
tered a dual antiplatelet of aspirin and prasugrel. This
study was designed, conducted, analysed and written
independently of industry or any other ﬁnancial sup-
port. All human studies have been approved by the
Nice Hospital ethics committee and have therefore
been performed in accordance with the ethical stand-
ards laid down in the 1964 Declaration of Helsinki and
its later amendments.
Setting
Two hundred patients with intracranial aneurysms
were treated using coiling and stenting procedures
between January 2009–February 2014 at the Nice
University Hospital in Nice, France. Group 1 consists
of the ﬁrst 100 patients treated between January 2009–
January 2012, while Group 2 consists of the remaining
100 patients treated between February 2012–February
2014. The same two senior surgeons operated on all the
patients in both groups.
The following data were analysed for both groups:
procedural and periprocedural haemorrhagic and
ischaemic complications in the six months following
the intervention; postoperative angiographic results;
clinical results collected one month after the interven-
tion; clinical results collected six months after the
intervention.
Participants
During the period of inclusion, all patients who were
subjected to coiling and stenting of non-ruptured intra-
cranial aneurysms or recurring aneurysms were
included in the study. Patients treated surgically were
excluded. Patients with ruptured aneurysms and sub-
jected to emergency stenting were excluded from the
study. Patients who received endovascular treatment
(coiling, coiling with balloon) without stenting were
also excluded from the study.
All patients in Group 1 received aspirin and clopido-
grel – the treatment involved a daily dose of 75mg of
aspirin and 75mg of clopidogrel, administered orally.
The treatment started seven days before the endovas-
cular intervention and continued for a period of at least
six months after embolization.
Group 2 patients received a dual antiplatelet of
aspirin and prasugrel. They did not receive any clopi-
dogrel. The seventh day before treatment, a 60mg load-
ing dose of prasugrel was administered to the patients;
then the treatment continued with a daily dose of 10mg
for a period of six months after embolization. Group 2
patients received the same dose of aspirin as the Group
1 patients.
MRI (magnetic resonance imaging) and/or CT scan
(computed tomography scanner) control was carried
out for patients with a clinical worsening after the
procedure.
Data sources: measurement
The following parameters were analysed in both
groups:
1. Clinical evaluations before and after (for a period of
1–6 months) the procedure were carried out by two
senior neurovascular surgeons. They scored the
results using the Modiﬁed Rankin Scale (mRS) in
order to assess the degree of clinical worsening suf-
fered by patients following the intervention.
2. Procedural thromboembolic complications: compli-
cations that were highlighted either in the angio-
grams during and after the embolization
procedure, either during the postoperative MRI
scans, carried out if there was a clinical worsening
after the procedure. Angiographic ﬁndings were clas-
siﬁed as follows: type 1: non-occlusive clot at parent
vessel coil interface or in stent; type 2: occlusive clot
in stent or in parent artery; type 3: distal emboli.
Both the absence or occurrence of intraoperative
thromboembolic complications and the type of compli-
cations were validated by a non-interventional neuror-
adiologist and a neurovascular surgeon who reviewed
and analysed the postoperative MRI, and the angio-
grams obtained during the embolization procedure.
1. Cerebral haemorrhage after endovascular treatment:
complications highlighted either by the extravascular
escape of the contrast ﬂuid during the angiogram or
the results of the post-embolization MRI scans and/
or CT scans carried out for patients with intracranial
bleeding symptoms.
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2. Other intraoperative complications related to the
procedure or occurring during the procedure (e.g.
coil migration).
3. Rescue treatments for complications.
4. Post-procedure aneurysm occlusion rate was assessed
using the modiﬁed Raymond Classiﬁcation.17
Efforts to address potential sources of bias
To reduce sources of bias in the study, the preventive
treatment of thromboembolic complications was the
only parameter that diﬀered between the two groups.
Statistical methods
First, descriptive statistics were estimated for each cov-
ariate within each treatment group (percentages for
qualitative covariates, mean and standard deviation
(SD) for quantitative ones). Second, bivariate statistical
tests were provided to compare the two treatment
groups: Pearson chi-square test for qualitative covari-
ates (or Fisher exact test if necessary) and Wilcoxon
non-parametric ranked test for quantitative covariates.
Statistical analyses were provided by using R3.1.3 soft-
ware, 2015 (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
Participants and methods
Participants. Two hundred and forty patients with non-
ruptured cerebral aneurysm were initially included.
Five patients treated by clipping and 35 patients treated
endovascularly but without stent were excluded. Two
hundred patients, treated using endovascular coil
embolization, were ﬁnally included in the study.
Group 1 characteristics (Table 1, Table 2). The endovascu-
lar stents used during the procedures were Leo stents
(Balt), except for two cases which used Solitaire
stents (Covidien Corp.), two other cases which
called for Neuroform stents (Stryker Corp.) and one
aneurysm which was treated using a ﬂow diverter
(Silk, Balt).
The method used for treating the 91 aneurysms was
the coiling of the aneurysmal sack assisted by balloon
remodelling and a ﬁnal stenting; 11 cases were treated
using ’jailing’ techniques.
Group 2 characteristics (Tables 1 and 2). The endovascular
stents used during the procedures were: ﬂow diverter
stents (Silk Balt) in 11 procedures; Leo stents (Balt)
in 81 procedures; Solitaire stents (Covidien Corp.) in
nine procedures. Four procedures called for a Y-shaped
stenting (using Solitaire stents).
The method used for treating the 77 aneurysms was
the coiling of the aneurysmal sack assisted by balloon
remodelling and a ﬁnal stenting; 28 cases were treated
using ’jailing’ techniques.
Main results
Initial comparability of groups 1 and 2 (Tables 1 and
2). Group 1 patients (clopidogrel) showed a signiﬁ-
cantly higher number of aneurysms located in the
area of the anterior communicating artery (p¼ 0.01)
and more treatments for recurrent aneurysms after ini-
tial coiling (p¼ 0.039).
Table 1. Population characteristics.
Group 1 (clopidogrel) Group 2 (prasugrel) p Value
Patients (n) 100 100
Sex (M/F) (31/62) (32/68) 0.87901
Age Mean 53 54 0.7945
Minimum 21 27
Maximum 73 81
Comorbidities
and history
Smokers (n) 47 48 0.8874
Chronic arterial hypertension (n) 43 43 1
Patients with history of aneurysm or
subarachnoid haemorrhage (n)
36 23 0.06
Polycystic kidney disease (n) 6 2 NSD
Familial cerebral aneurysmal disease (n) 3 4 NSD
History of ischaemic stroke (n) 4 6 NSD
History of peripheral arterial occlusive
disease and/or coronary heart disease (n)
4 4 NSD
mRS before the
procedure
mRS 0 (n) 93 88 0.2279
mRS 1 (n) 7 12 0.2279
mRS 2 and more (n) 0 0 0
mRS: Modified Rankin Score; NSD: no significant difference.
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Although the size of the aneurysms was constant
across the two groups, the number of wide-necked
aneurysms was signiﬁcantly higher in Group 2 prasu-
grel (p¼ 0.011). Apart from these three ﬁndings, there
were no statistical diﬀerences registered among the
populations (as seen in Tables 1 and 2).
In terms of procedural methods, the two groups
were set apart by a more frequent use of ﬂow diverter
stent in Group 2 prasugrel (11 procedures) compared to
Group 1 clopidogrel (one procedure) (p¼ 0.005).
Aneurysmal occlusion (Table 2). Aneurysmal occlusion
rates were identical in both groups. Group 1 had
73 completely occluded aneurysms and Group 2
had 71 (p¼ 0.53); 27 aneurysms in Group 1 and 26
aneurysms in Group 2 were classiﬁed as class 2 on
the Raymond scale (p¼ 0.77). Class 3 was more
frequent in Group 2 (eight in Group 2 as opposed
to two in Group 1); however, this diﬀerence was not
that signiﬁcant (p¼ 0.1).
Total number of complications (Table 3). Group 1 presented
25 complications (20 intraoperative and ﬁve additional
with 30 days) versus 18 (12 intraoperative and six post-
operative) in Group 2. This was not statistically signiﬁ-
cant (p¼ 0.52) but there was a statistical signiﬁcant
ﬁnding in the morbidity at 30 days and six months
between the groups.
No deaths were recorded across the two groups. No
complications were observed in the postoperative stage
across the two groups between Day 30 and the sixth
month following the intervention. Six months after the
Table 2. Aneurysms and procedures.
Group 1
(clopidogrel)
Group 2
(prasugrel) p Value
Aneurysms/ procedures (n) 102 105
Indication Asymptomatic aneurysm (n) 77 86 0.25941
Recurrent aneurysm (n) 25 14 0.03979
Compressive aneurysm (n) 0 5 0.05962
Location ACI 35 36 0.99661
Co Ant 32 17 0.0102
MCA 25 37 0.09204
ACA 4 4 1
Post circ. 6 11 0.22877
Size (>10mm) 25 31 0.41687
Neck (large) 61 80 0.01143
Postop aneurysm occlusiona Score 1 73 71 0.53696
Score 2 27 26 0.77824
Score 3 2 8 0.10122
Flow diverter stent (n) 1 11 0.005
ACA: anterior cerebral artery; ACI: internal carotid artery; Co Ant: anterior communicating artery; MCA: middle cerebral artery; Post circ.: posterior
circulation.
aRaymond Scale.17
Bold face values for significant p.
Table 3. Complications.
Overall
complications
Clinical
worsening day 30
Thromboembolic
complications
Hemorrhagic
complications
Other operative
complicationsOverall
Stent thrombosis
(type 2) Intracranial Extracranial
Overall
Group 1 (clopidogrel)
(100 patients)
25 15 17 3 2 3 3
Group 2 (prasugrel)
(100 patients)
18 6 12 0 2 4 1
p Value 0.5229 0.0379 0.315 p¼ 0.2 1 0.898 0.621
Bold face values for significant p.
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intervention, 10 patients in Group 1 showed a clinical
worsening related to the intervention (seven classiﬁed as
one on the mRS scale, two classiﬁed as two on the mRS
scale and one classiﬁed as three on the mRS scale).
However, in Group 2, only four patients had not
returned to their initial clinical state (three classiﬁed
as one on the mRS scale and one classiﬁed as three
on the mRS scale).
Intra- and extracranial haemorrhagic complications were com-
parable in both groups (p¼ 1) (Table 3). In both groups,
intra-operative bleeding was observed only for a single
patient. Bleeding was not spontaneous: it resulted from
mechanical perforation by the microwire with extravasa-
tion of contrast. In both, inﬂation of the remodelling bal-
loon and placement of a coil stopped the haemorrhage.
TheGroup 1patient (clopidogrel)was hemiplegic on awa-
kening and postoperative CT scans revealed a small-sized
cerebral hematoma; the patient’s condition was classiﬁed
as two on the mRS scale one month after the intervention
and as one on the mRS scale six months after the inter-
vention. The Group 2 patient (prasugrel) showed a small
meningeal haemorrhage, which produced headaches
during the ﬁrst week after the operation without any evi-
dence of neurological disorders. In Group 2 (prasugrel)
another case of intracranial bleeding (low-volume intra-
ventricular haemorrhage) was discovered following acute
headaches, one week after the intervention.
In addition to these intracranial haemorrhages, four
haematomas in the groin area were observed in each
group. Three weeks after the intervention, one patient
in Group 2 (prasugrel) presented a gastric haemorrhage
from peptic ulceration. Aspirin was stopped for three
weeks and no further haemorrhage occurred.
Thromboembolic complications (Table 3). Intraoperative
thromboembolic complications in the 30 days following
the procedure were higher in Group 1 clopidogrel (17
patients in Group 1 versus 12 patients in Group 2), but
not statistically signiﬁcant (p¼ 0.31).
No thromboembolic complications were observed
after Day 30, as most of the complications occurred
during the intraoperative stage (16 out of 17 in
Group 1; 10 out of 12 in Group 2).
In Group 2 prasugrel, thrombo-embolic complica-
tions consisted mainly of small distal emboli, which
were visible on the intraoperative angiograms (three
patients) or during the postoperative MRI scans (four
patients), but no proximal artery occlusion and no stent
thrombosis was observed. However, in the Group 1
clopidogrel, three patients showed symptomatic prox-
imal artery thrombosis (two stent thrombosis during
the intraoperative stage and one stent thrombosis
occurred on Day 5).
Other intraoperative events were very similar in both groups
(p¼ 0.621) (Table 3). The following events were observed
in Group 1: an allergy to curare, which resulted in ana-
phylactic shock after the induction of anaesthesia; one
coil rupture and one bad opening stent. In Group 2,
only a coil rupture was observed.
Discussion
Compared to simple coiling procedures or balloon
assisted coiling, procedures that combine stenting and
coiling can reduce risks of aneurysm recurrence after an
endovascular treatment.1,12,18,19
However, intracranial stenting, mostly indicated in
the treatment of non-ruptured lesions, increases the risk
of thromboembolic complications as opposed to simple
coiling procedures, in spite of the dual antiplatelet.1–12
Thromboembolic complications vary between 7%20
and 20%.21,22 More serious thromboembolic complica-
tions are intrastent thrombosis which, according to
McLaughlin et al.,23 can manifest in 4.6% of cases.
The dual antiplatelet surrounding stenting proced-
ures mostly consists of aspirin and clopidogrel.12
Aside from the thrombogenicity of intracranial
stents, the increase in intraoperative or postoperative
thromboembolic events can be explained by the incon-
stant eﬀectiveness of clopidogrel, ineﬀective for 5–11%
of patients.13,24–26 The measurement of platelet inhib-
ition level after clopidogrel administration is useful in
quantifying the risk of thromboembolic complication in
subjects undergoing endovascular treatment using
implantable materials27,28 and a signiﬁcant association
was observed between perioperative thromboembolic
events and low-responders to clopidogrel.24,25,27–30
The concept of a ‘tailored treatment’ by increasing clo-
pidogrel dosing according to the degree of responsive-
ness of a given patient assessed by a platelet function
assay is well known in cardiology, but for some
authors31 there is not a standardised platelet function
test able to identify low-responders to clopidogrel in an
easy and conclusive way; for others, the beneﬁt of this
strategy is not clear26,32 and, ﬁnally, major bleedings
are more common with double-dose than with stan-
dard-dose clopidogrel.33
Novel antiplatelet drugs were found to be an alter-
native to clopidogrel resistance; among them, prasu-
grel, a third generation thienopyridine, that needs
hepatic biotransformation into its active metabolite to
irreversibly block the P2Y12 receptor.34
Prasugrel has several pharmacological advantages
over clopidogrel, because it is more eﬀectively con-
verted into its active metabolite and displays a faster
onset of action and greater degree of platelet inhibition
with less variability in response, even when compared
with high-dose clopidogrel.34
Cardiology studies showed that patients who receive
prasugrel exhibit major haemorrhages more frequently
than patients who receive clopidogrel, especially in
patients with previous strokes, elderly patients (more
than 75 years) and slim patients (weight lower than
60 kg).33,35 However, the increased risks associated
with prasugrel were not found in other cardiology
series,36,37 Until now, usage of prasugrel in
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cerebrovascular diseases ﬁeld has been limited16,38–42 by
the fear of risk of intracranial haemorrhage. While
Akbari et al.39 described nine complications involving
cerebral and extracerebral haemorrhages (out of 25
procedures), a more recent study,42 had contradictory
conclusions with a very low rate of haemorrhagic
complications. This study compared the eﬃcacy of
two antiplatelet medications, low-dose prasugrel and
clopidogrel, in 194 patients undergoing endovascular
treatment of unruptured aneurysms and, as for our
study, did not show any signiﬁcant diﬀerence between
the two groups in terms of intraoperative or postopera-
tive haemorrhages. The low number of haemorrhagic
complications, in the prasugrel group, compared to car-
diology studies43,44 might be due to the selection of
patients subjected to treatments aimed to preventing
cerebral aneurysms ruptures (good general health,
age< 75 years). In terms of extracerebral haemorrhagic
complications, although the number of haematomas at
the puncture point was nearly consistent across the two
groups involved in our study, one patient in Group 2
prasugrel exhibited an ulcerous gastric haemorrhage in
the 30 days following the procedure, which called for an
endoscopy and a temporary stop of prasugrel. This gas-
tric complication was already reported in the study of
Akbari et al.39 and, as such, could imply the need for
patients to be checked for gastric ulcer antecedents
before being prescribed a prasugrel treatment.
In cardiology, clinical trials have shown that prasu-
grel reduced the incidence of ischaemic events in
patients with acute coronary syndrome, compared
with clopidogrel.35,37,43,45,46 In terms of endocerebral
procedures, the most important studies come to contra-
dictory conclusions. As such, the study of Akbari
et al.39 showed no diﬀerences in thromboembolic com-
plications in 25 patients treated with prasugrel com-
pared with 51 patients treated with clopidogrel, and
the study of Stetler et al.38 did not report any thrombo-
embolic complications with prasugrel. In the recent
study of Ha and colleagues,42 including the treatment
of 194 patients, the authors found thromboembolic
complications neither in the prasugrel group nor in
the clopidogrel group. The number of thrombo-
embolic events observed in the two groups of our
study did not diﬀer signiﬁcantly. An important
thing to mention in regard this ﬁnding is that the
two groups were quite diﬀerent in terms of operative
risks: the prasugrel group had a signiﬁcantly higher
number of wide-necked aneurysms and was subjected
to more procedures with a stent ﬂow diverter, which
is associated with higher risk of thromboembolic
complications.47,48
Moreover, serious thromboembolic events, such as
complete thrombosis of the stent, were not observed in
the prasugrel group, whereas they occurred three times
in the clopidogrel group. The benign character of com-
plications that occurred in the prasugrel group
accounts for the signiﬁcant diﬀerence in clinical results
between the two groups on Day 30.
Our study is not without limitations, including: a
study population derived from both retrospective and
prospective data; two consecutive populations that are
diﬀerent in terms of the locations in which the
aneurysms have occurred, the number of wide-necked
aneurysms, the use of ﬂow diverter stents etc.; the
majority of patients have undergone treatments aimed
to prevent cerebral aneurysms rupture which makes it
hard to generalise the results obtained in this study; the
lack of systematic postoperative MRI scans.
Conclusions
The use of prasugrel instead of clopidogrel in the anti-
platelet treatment accompanying the endovascular
treatment of non-ruptured cerebral aneurysms can
potentially decrease the clinical consequences of intrao-
perative and postoperative thromboembolic complica-
tions without increase of haemorrhagic events.
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